Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.

Zhou C, Yang X, Wang Y, Xi J, Pan H, Wang M, Zhou Y, Xiao Y

Human reproduction (Oxford, England)1 Jul 2022Cited by 43 (Europe PMC)

PMID35595223DOI10.1093/humrep/deac114PepBankPUB-35595223

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone15

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, retrieved oocyte counts were comparable with dual triptorelin-hCG trigger and hCG alone.
In plain wordsIn advanced-age IVF/ICSI patients, retrieved oocyte counts were similar with dual triptorelin-hCG trigger and hCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeRetrieved oocyte count versus hCG
Study
n: not reported in source
Comparator
hCG alone
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Retrieved oocytes
4.08 oocytes
dual trigger
Retrieved oocytes
3.6 oocytes
hCG alone
Source sentences
Summary
However, the number of retrieved oocytes in the dual trigger group was comparable with those in the hCG group (4.08 ± 2.79 vs 3.60 ± 2.71, P = 0.080) and the GnRHa group (4.08 ± 2.79 vs 3.81 ± 3.38, P = 0.101)
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522303
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, retrieved oocyte counts were comparable with dual triptorelin-hCG trigger and triptorelin alone.
In plain wordsIn advanced-age IVF/ICSI patients, retrieved oocyte counts were similar with dual triptorelin-hCG trigger and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeRetrieved oocyte count versus triptorelin
Study
n: not reported in source
Comparator
Triptorelin alone
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Retrieved oocytes
4.08 oocytes
dual trigger
Retrieved oocytes
3.81 oocytes
triptorelin alone
Source sentences
Summary
However, the number of retrieved oocytes in the dual trigger group was comparable with those in the hCG group (4.08 ± 2.79 vs 3.60 ± 2.71, P = 0.080) and the GnRHa group (4.08 ± 2.79 vs 3.81 ± 3.38, P = 0.101)
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522304
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, two-pronuclei embryo counts were comparable across the dual triptorelin-hCG, hCG-only, and triptorelin-only groups.
In plain wordsIn advanced-age IVF/ICSI patients, two-pronuclei embryo counts were similar across the dual triptorelin-hCG, hCG-only, and triptorelin-only groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTwo-pronuclei embryo count
Study
n = 510
Comparator
hCG alone and triptorelin alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
comparable data between the groups were also found when analyzing the number of 2PN embryos and the 2PN rate.
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522305
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, two-pronuclei rates were comparable across the dual triptorelin-hCG, hCG-only, and triptorelin-only groups.
In plain wordsIn advanced-age IVF/ICSI patients, two-pronuclei rates were similar across the dual triptorelin-hCG, hCG-only, and triptorelin-only groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTwo-pronuclei rate
Study
n = 510
Comparator
hCG alone and triptorelin alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
comparable data between the groups were also found when analyzing the number of 2PN embryos and the 2PN rate.
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522307
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased good-quality embryo counts versus hCG alone (1.74 versus 1.19).
In plain wordsIn advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger produced more good-quality embryos than hCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseGood-quality embryo count versus hCG
Study
n: not reported in source
Comparator
hCG alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Good-quality embryo count
1.74 embryos
dual trigger
Good-quality embryo count
1.19 embryos
hCG alone
Source sentences
Summary
In the dual trigger group, the numbers of good-quality embryos and viable embryos were both significantly higher than in the hCG group (1.74 ± 1.90 vs 1.19 ± 1.45, P = 0.016 and 2.19 ± 2.11 vs 1.56 ± 1.66, P = 0.008, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522309
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased good-quality embryo counts versus triptorelin alone (1.74 versus 1.20).
In plain wordsIn advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger produced more good-quality embryos than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseGood-quality embryo count versus triptorelin
Study
n: not reported in source
Comparator
Triptorelin alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Good-quality embryo count
1.74 embryos
dual trigger
Good-quality embryo count
1.2 embryos
triptorelin alone
Source sentences
Summary
and the GnRHa group (1.74 ± 1.90 vs 1.20 ± 1.67, P = 0.003 and 2.19 ± 2.11 vs 1.45 ± 1.75, P = 0.001, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522311
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, frozen-transfer live birth rate was higher with dual triptorelin-hCG than triptorelin alone (32.6% versus 14.1%).
In plain wordsIn advanced-age IVF/ICSI patients, frozen-transfer live birth rate was higher with dual triptorelin-hCG than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFrozen-transfer live birth rate versus triptorelin
Study
n: not reported in source
Comparator
Triptorelin alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Live birth rate after frozen ET
32.6%
dual trigger
Live birth rate after frozen ET
14.1%
triptorelin alone
Source sentences
Summary
The live birth rate and ongoing pregnancy rate after frozen ET in the dual trigger group were significantly higher than those in the GnRHa group (32.6% vs 14.1%, P = 0.007 and 34.8% vs 17.6%, P = 0.013, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522314
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, frozen-transfer live birth rate did not significantly differ with dual triptorelin-hCG versus hCG alone (32.6% versus 27.9%).
In plain wordsIn advanced-age IVF/ICSI patients, frozen-transfer live birth rates were similar with dual triptorelin-hCG and hCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFrozen-transfer live birth rate versus hCG
Study
n: not reported in source
Comparator
hCG alone
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Live birth rate after frozen ET
32.6%
dual trigger
Live birth rate after frozen ET
27.9%
hCG alone
Source sentences
Summary
but not superior to those in the hCG group (32.6% vs 27.9%, P = 0.537 and 34.8% vs 27.9%, P = 0.358, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522316
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, fresh-transfer pregnancy outcomes were comparable across dual triptorelin-hCG, hCG-only, and triptorelin-only groups.
In plain wordsIn advanced-age IVF/ICSI patients, fresh-transfer pregnancy outcomes were similar across dual triptorelin-hCG, hCG-only, and triptorelin-only groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePregnancy outcomes after fresh embryo transfer
Study
n = 510
Comparator
hCG alone and triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Pregnancy outcomes after fresh embryo transfer (ET) were comparable between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522313
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased retrieval rate versus hCG alone (87.9% versus 84.1%).
In plain wordsIn advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased retrieval rate compared with hCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseOocyte retrieval rate versus hCG
Study
n: not reported in source
Comparator
hCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Retrieval rate
87.9%
dual trigger
Retrieval rate
84.1%
hCG alone
Source sentences
Summary
The dual trigger was associated with a higher retrieval rate (87.9% vs 84.1% in the hCG group, P = 0.031; 87.9% vs 83.6% in the GnRHa group, P = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522301
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased retrieval rate versus triptorelin alone (87.9% versus 83.6%).
In plain wordsIn advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased retrieval rate compared with triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseOocyte retrieval rate versus triptorelin
Study
n: not reported in source
Comparator
Triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Retrieval rate
87.9%
dual trigger
Retrieval rate
83.6%
triptorelin alone
Source sentences
Summary
The dual trigger was associated with a higher retrieval rate (87.9% vs 84.1% in the hCG group, P = 0.031; 87.9% vs 83.6% in the GnRHa group, P = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522302
12HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased viable embryo counts versus hCG alone (2.19 versus 1.56).
In plain wordsIn advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger produced more viable embryos than hCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseViable embryo count versus hCG
Study
n: not reported in source
Comparator
hCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Viable embryo count
2.19 embryos
dual trigger
Viable embryo count
1.56 embryos
hCG alone
Source sentences
Summary
In the dual trigger group, the numbers of good-quality embryos and viable embryos were both significantly higher than in the hCG group (1.74 ± 1.90 vs 1.19 ± 1.45, P = 0.016 and 2.19 ± 2.11 vs 1.56 ± 1.66, P = 0.008, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522310
13HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger increased viable embryo counts versus triptorelin alone (2.19 versus 1.45).
In plain wordsIn advanced-age IVF/ICSI patients, dual triptorelin-hCG trigger produced more viable embryos than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseViable embryo count versus triptorelin
Study
n: not reported in source
Comparator
Triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Viable embryo count
2.19 embryos
dual trigger
Viable embryo count
1.45 embryos
triptorelin alone
Source sentences
Summary
and the GnRHa group (1.74 ± 1.90 vs 1.20 ± 1.67, P = 0.003 and 2.19 ± 2.11 vs 1.45 ± 1.75, P = 0.001, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522312
14HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, frozen-transfer ongoing pregnancy rate was higher with dual triptorelin-hCG than triptorelin alone (34.8% versus 17.6%).
In plain wordsIn advanced-age IVF/ICSI patients, frozen-transfer ongoing pregnancy rate was higher with dual triptorelin-hCG than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFrozen-transfer ongoing pregnancy versus triptorelin
Study
n: not reported in source
Comparator
Triptorelin alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Ongoing pregnancy rate after frozen ET
34.8%
dual trigger
Ongoing pregnancy rate after frozen ET
17.6%
triptorelin alone
Source sentences
Summary
The live birth rate and ongoing pregnancy rate after frozen ET in the dual trigger group were significantly higher than those in the GnRHa group (32.6% vs 14.1%, P = 0.007 and 34.8% vs 17.6%, P = 0.013, respectively)
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522315
15HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In advanced-age IVF/ICSI patients, frozen-transfer ongoing pregnancy rate did not significantly differ with dual triptorelin-hCG versus hCG alone (34.8% versus 27.9%).
In plain wordsIn advanced-age IVF/ICSI patients, frozen-transfer ongoing pregnancy rates were similar with dual triptorelin-hCG and hCG alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFrozen-transfer ongoing pregnancy versus hCG
Study
n: not reported in source
Comparator
hCG alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Ongoing pregnancy rate after frozen ET
34.8%
dual trigger
Ongoing pregnancy rate after frozen ET
27.9%
hCG alone
Source sentences
Summary
but not superior to those in the hCG group (32.6% vs 27.9%, P = 0.537 and 34.8% vs 27.9%, P = 0.358, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Women aged ≥35 years undergoing IVF/ICSI treatment, receiving a non-pituitary down-regulation protocol, and with low risk of OHSS, were enrolled in this trial.
Summary · context
On the trigger day, patients were randomized into three groups: hCG alone (who received 6000 IU of hCG), GnRHa alone (who received 0.2 mg of triptorelin) and dual trigger (who received 0.2 mg of triptorelin plus 2000 IU of hCG) groups.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-3559522317

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.